8 completed. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 1 | 1 | Completed 1 |
Follow Leukoplakia: new trials by email Literature Review of Leukoplakia trials Research Report on Leukoplakia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia Nivolumab - Leukoplakia, Oral | Phase 2 | Completed | Dana-Farber Cancer Institute | 33 | 2018-12-05 | 2024-10-01 |
| Treatment of Oral Premalignant Lesions With 5-ALA PDT PDL-585, ScleroPLUS laser, 5-Aminolevulinic Acid (Levulan KerastickTM), Fluorescence Diagnosis Imaging - Leukoplakia, Erythroplakia | Phase 1 / Phase 2 | Completed | University of Arkansas | 29 | 2007-01-01 | 2015-03-24 |
| Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia rosiglitazone maleate, laboratory biomarker analysis - Oral Leukoplakia | Phase 2 | Completed | National Cancer Institute (NCI) | 25 | 2006-06-01 | 2013-02-13 |
| Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia celecoxib - Head and Neck Cancer, Precancerous Condition | Phase 2 | Completed | Fox Chase Cancer Center | 2003-11-01 | 2013-07-11 | |
| Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia pioglitazone hydrochloride - Head and Neck Cancer, Oral Leukoplakia | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2003-06-01 | 2022-02-11 |
| Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract Porfimer Sodium, Photodynamic Therapy - Head and Neck Cancer, Precancerous/Nonmalignant Condition | Phase 2 | Completed | University of Miami | 45 | 2003-06-01 | 2017-02-08 |
| Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Bowman-Birk inhibitor concentrate, placebo, laboratory biomarker analysis - Lip and Oral Cavity Cancer, Oral Leukoplakia | Phase 2 | Completed | National Cancer Institute (NCI) | 325 | 1999-01-01 | 2014-12-19 |
| Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR Ketorolac Rinse - Leukoplakia, Periodontal Disease | Phase 2 | Completed | National Cancer Institute (NCI) | 57 | 1998-06-01 | 2008-03-04 |
Leukoplakia, Oral (6) · Head and Neck Neoplasms (3) · Mouth Neoplasms (2) · Oropharyngeal Neoplasms (2) · Precancerous Conditions (2) · Tongue Neoplasms (2) · Erythroplasia (1) · Hypopharyngeal Neoplasms (1) · Nasopharyngeal Neoplasms (1) · Periodontal Diseases (1) · Squamous Cell Carcinoma of Head and Neck (1)
Neoplasms (8) · Pathological Conditions, Anatomical (8) · Pathological Conditions, Signs and Symptoms (8) · Mouth Diseases (7) · Stomatognathic Diseases (7) · Neoplasms by Site (6) · Precancerous Conditions (6) · Mouth Neoplasms (4) · Head and Neck Neoplasms (3) · Otorhinolaryngologic Diseases (2) · Otorhinolaryngologic Neoplasms (2) · Pharyngeal Diseases (2) · Pharyngeal Neoplasms (2) · Tongue Diseases (2)
Aminolevulinic Acid (1) · Celecoxib (1) · Dihematoporphyrin Ether (1) · Nivolumab (1) · Photochemotherapy (1) · Pioglitazone (1) · Rosiglitazone (1)
National Cancer Institute (NCI) (4) · Dana-Farber Cancer Institute (1) · Fox Chase Cancer Center (1) · University of Arkansas (1) · University of Miami (1)
United States (8)
Francisco Civantos, Jr., MD (1) · Frank Meyskens (1) · Frank Ondrey (1) · Gal Shafirstein, PhD (1) · Glenn Hanna, MD (1) · Jay Boyle (1) · Paul F. Engstrom, MD (1)
PMID 14520092, PMID 22106236, PMID 23055220, PMID 23639862, PMID 37971722, PMID 39532605, PMID 39584361
N01CN35159 (1), P30CA008748 (1), P30CA016672 (1), U01CA072294 (1)